HighTower Advisors
KYNB icon

HighTower Advisors’s Kyntra Bio KYNB Stock Holding History

HighTower Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8
Closed -$2K – 2310
2019
Q4 		$2K Buy
+8
New +$8.17K ﹤0.01% 2247

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HighTower Advisors's KYNB Position: Q2 2026 in Review

HighTower Advisors increased its Kyntra Bio (KYNB) stake by 0.01% in Q2 2026, buying an estimated $14 and bringing the position to 39,746 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #3217.

HighTower Advisors first reported a position in KYNB in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.88M in Q3 2020. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • HighTower Advisors held 39,746 shares of Kyntra Bio worth $300K as of Q2 2026.
  • HighTower Advisors bought 2 Kyntra Bio shares in Q2 2026, an estimated $14.
  • Kyntra Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3217 holding.
  • HighTower Advisors first reported a position in Kyntra Bio in Q4 2018 and has held it in 31 quarters since.
  • HighTower Advisors's Kyntra Bio position peaked at $2.88M in Q3 2020.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.